Skip directly to content


Besponsa® is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI). 1


1. Besponsa® (inotuzumab ozogamicin) Prescribing Information. Pfizer Corporation Hong Kong Limited Version (Nov 2018)

[PP-CPF-HKG-0070] SEP 2019

Therapeutic Area Sub Category: